| UHC Commercial Medical & Drug | Medical Therapies for Enzyme Deficiencies – Commercial Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Obstructive and Central Sleep Apnea Treatment – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Otoacoustic Emissions Testing (For Oxford Only) – Oxford Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Pharmacogenetic Panel Testing – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Preventive Care Services – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Provider Administered Drugs – Site of Care – Commercial Medical Benefit Drug Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Respiratory Pathogen Nucleic Acid Detection Testing – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC Commercial Medical & Drug | Stereotactic Body Radiation Therapy and Stereotactic Radiosurgery – Commercial and Individual Exchange Medical Policy | 2026-10-01 |